A new simian-human immunodeficiency virus (SHIV), carrying env from an uncloned HIV-1 subtype C clinical isolate (97ZA012), was generated through intracellular homologous recombination, a DNA repair mechanism of the host cell. PCR fragments amplified from an existing SHIV plasmid (a 7-kb fragment from the 5 end and a 1.5-kb fragment from the 3 end) and a 4-kb fragment amplified from 97ZA012 cDNA containing env were co-transfected to human lymphoid cells. The resulting recombinant was subjected to serial passage in rhesus peripheral blood mononuclear cells (RhPBMCs).
8 rhesus macaques (Passage #4). The virus replicated robustly to a high titer, reaching 1,850 cpm/µl supernatant equivalent on day 5, followed by a rapid decline (Fig. 2D ). To confirm the observation, we inoculated supernatant collected on day 5 of Passage #4 into another RhPBMC preparation without manipulation a second time (Passage #5). The virus reproducibly replicated in primary monkey cells, with a peak of RT activity on day 5 post-infection (2,280 cpm; Fig. 2E ). We concluded that a new recombinant virus capable of replicating in RhPBMCs was generated/evolved through IHR/in vitro passage. We designated the culture supernatant collected on day 5 from Passage #5 as SHIV 97ZA012
and subjected it to further characterization.
Genomic organization of SHIV 97ZA012
To elucidate the genomic organization of SHIV 97ZA012, the nt sequence was determined on cDNA that was reverse-transcribed from virion-associated viral genomic RNA prepared from the culture supernatant. The obtained sequence was compared with those of SHIV KS661 and HIV-1 97ZA012 (Fig. 3) . Genomic analysis revealed that the 5 and 3 breakpoints were at the 282nd nt of env gp120, upstream of the V1/V2 loop, and the 756th nt of the env gp41 cytoplasmic domain, respectively (Fig. 3A) . The breakpoints that gave rise to replication-competent virus were not necessarily at the interface of genes juxtaposed to each other. This is also the case in many CRFs of HIV-1, examples of naturally occurring recombinants (Carr et al., 2001; Guimaraes et al., 2008; Koulinska et al., 2001; Perez et al., 2006; Piyasirisilp et al., 2000) .
SimPlot (Lole et al., 1999) analysis revealed that the genomic fragment derived from HIV-1 97ZA012 did not completely match the registered sequence of the virus (GenBank Accession No. AF286227). To ascertain that the recombinant virus indeed carries the env sequence derived from HIV-1 97ZA012, we conducted a phylogenetic analysis of the sequence with the corresponding region of HIV-1 strains belonging to subtype B or C, including the registered sequence of 97ZA012 (Fig. 3B) . The supposed 97ZA012-derived sequence naturally formed a subcluster with the registered sequence and was positioned in the cluster of subtype C strains in the phylogenetic tree. We concluded that the observed difference in sequences between SHIV 97ZA012 and the registered HIV-1 97ZA012 was within the extent of quasispecies of a single isolate.
Replication properties of SHIV 97ZA012 in C8166-CCR5 cells and RhPBMCs
To characterize the replication properties of SHIV 97ZA012, we inoculated the virus into human C8166-CCR5 cells and RhPBMCs. Because HIV-1 is unable to 1 2 3 4 5 6 7 8 9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 10 control viruses, to a co-receptor usage assay. Each virus, normalized by an infectious unit, was inoculated to RhPBMCs in the presence of 5 µM AMD3100 (a small-molecule CXCR4 inhibitor), AD101 (a small-molecule CCR5 inhibitor), or both. Virus replication was monitored for 7 days by virion-associated RT activity release in the culture supernatant ( Fig. 5 ). SIV239, which has been established as a CCR5-utilizing virus, replicated to a high titer in the absence of any inhibitor (Fig. 5A ). AMD3100 had little impact on the replication of the virus, as described previously (Zhang et al., 2000) . In the presence of AD101 or both inhibitors, however, replication of SIV239 was substantially impaired. In contrast, SHIV KS661, which has been reported to predominantly utilize CXCR4 as an entry co-receptor (Matsuda et al., 2010) , exhibited a replication profile opposite to that of SIV239: no impairment of replication in the presence of AD101, but remarkably delayed replication in the presence of AMD3100, and complete suppression in the presence of both inhibitors ( Fig. 5B ). When control viruses exhibited the replication profiles described above, SHIV 97ZA012 exhibited a replication profile similar to that of SIV239: no impact on replication in the presence of AMD3100, but complete suppression when AD101 was present in the culture (Fig. 5C ). Based on these results, we concluded that SHIV 97ZA012 is a CCR5-utilizing virus, as is the parental HIV-1 97ZA012 in human cells.
Replication of SHIV 97ZA012 in macrophages
Many CCR5-utilizing HIV-1 strains replicate in monocyte-derived macrophages, which is a biological property called "macrophage tropism." Macrophage tropism has been shown to be associated with viral neurotropism (Gorry et al., 2001) , a subject to be investigated in non-human primate AIDS models. To clarify the biological property of the virus in macrophages, SHIV 97ZA012, along with macrophage-tropic and non-macrophage-tropic viruses, normalized by RT activity was inoculated to rhesus macaque primary alveolar macrophage (RhAM) cultures prepared from three uninfected animals. Virus replication was monitored by virion-associated RT activity released in the culture supernatant ( Fig. 6) . Overall, the viruses exhibited consistent replication profiles among cell cultures prepared from different individuals ( Fig. 6A-C) . SIV316, a macrophage-tropic variant of SIV239 (Desrosiers et al., 1991) , replicated to the highest titers among the viruses, reaching a peak around days 7-9 post-infection (2,000-2,500 cpm/µl). SHIV3-3, a macrophage-tropic SHIV (Igarashi et al., 2007) , exhibited a delayed replication profile and reached titers of >1,000 cpm/µl after 17 days 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 11 post-infection. In contrast, SIV239, which is reportedly incapable of replicating in cells of this type (Mori et al., 1993) , produced no measurable RT activity in the supernatant during the observation period. Under this condition, SHIV 97ZA012 replicated productively, although not as robustly as SIV316 or SHIV 3-3, and reached peak virus replication on day 9 post-infection (400-600 cpm/µl). Based on these results, we concluded that SHIV 97ZA012 is macrophage tropic.
Experimental infection of rhesus macaques with SHIV 97ZA012
Biological properties of the newly generated SHIV 97ZA012 revealed in the study, including CCR5 utilization, a robust replication profile in RhPBMCs, and infectiousness in primary macrophages, justified experimental infection of monkeys with the virus. Prior to the infection, we prepared an ample volume of animal challenge stock of the virus by inoculating SHIV 97ZA012 seed to RhPBMCs. Culture supernatant was collected daily and assessed for virus replication by RT activity. Fractions of culture supernatant collected on days 8 and 9 that exhibited the highest RT activities (2,450 and 2,550 cpm/µl supernatant equivalent, respectively) were combined, filtered through a 0.45-µm membrane, divided into aliquots designated SHIV 97ZA012 animal challenge stock, and stored in liquid nitrogen. The infectious titer of the virus stock was 1.51 × 10 4 TCID 50 /ml, and retention of its preference for CCR5 as an entry co-receptor was verified (data not shown).
The animal challenge stock of SHIV 97ZA012, 1 × 10 5 TCID 50 , was intravenously inoculated into each of three rhesus macaques. Virus replication was monitored by viral RNA load in plasma samples that were collected periodically ( Fig. 7) .
The virus replicated to substantially high titers in all three animals, reaching an initial peak of 1.03 × 10 8 copies/ml for MM533, 4.52 × 10 6 copies/ml for MM535, and 1.83 × 10 8 copies/ml for MM536 at week 1.1 (day 8) post-inoculation ( Fig. 7A ). After the initial peak, viral burdens of all three animals declined somewhat, but remained at approximately 1 × 10 6 copies/ml between weeks 3 and 5. One of the animals, MM533, was found to be lethargic and subsequently died at week 4. The cause of death was not related to primate lentivirus infection. The plasma viral burdens of the remaining two animals gradually declined from week 6 onward, resulting in barely detectable levels at week 20 (650 copies/ml for MM535 and 740 copies/ml for MM536).
7B). Although all three animals experienced a transient decrease in cell numbers, the cell numbers promptly rebounded thereafter and basically stabilized after week 8 for MM535 and week 6 for MM536.
SIV and HIV-1 preferentially replicate at an "effector site," such as the mucosal tissues of the genital organs, lung, and gastrointestinal tract, where CCR5-positive effector memory CD4 + T lymphocytes, the primary viral target cells, predominantly reside. Here, they cause substantial depletion of cells during the acute phase of infection (Brenchley et al., 2004; Okoye et al., 2007; Veazey et al., 1998; Veazey et al., 2003) .
Because SHIV 97ZA012 utilizes the CCR5 molecule as an entry coreceptor, it was envisaged that the virus depletes effector memory CD4 + T lymphocytes as do SIV and HIV-1. We examined the fluctuation in CD4 + T lymphocytes in the pulmonary space of SHIV 97ZA012-infected animals as the representative effector site because the procedure causes the least severe insult to animals, allowing us to conduct frequent monitoring. It is known that SIV 239 infection results a substantial depletion of pulmonary CD4 + T cells in infected rhesus macaques, along with depletion of the cells in the gastrointestinal tract (Okoye et al., 2007) . In contrast to the cells in circulation, CD4 + T cells in the alveolar space exhibited a substantial decline during the acute phase of SHIV 97ZA012 infection ( Fig. 7C ). The percentages of cells dropped from 48.5%, 52.1%, and 44.7% for MM533, MM535, and MM536, respectively, on day 0 to 6.3% for MM533 at week 2.7, 16.8% for MM535 at week 5, and 2.6% for MM536 at week 2.7. The alveolar CD4 + T lymphocytes remained at low levels in the animals until week 11, then gradually increased toward pre-infection levels. Based on the results described above, it was concluded that SHIV 97ZA012 robustly replicated during the acute phase of infection, causing remarkable reduction of CD4 + T cells in the alveolar space. However, the animals eventually controlled the virus replication. SHIV 97ZA012 thus appeared to be less likely to cause disease in monkeys.
Multiple reports on the evolution of primate lentivirus through animal-to-animal passage have shown that initially less-efficiently replicating and non-pathogenic viruses transform to replication-competent and highly pathogenic viruses (Joag et al., 1996; Reimann et al., 1996; Sharma et al., 1992) . We applied this strategy to SHIV 97ZA012. At week 10.7, the axillary lymph nodes were collected from animals MM535 and MM536. Cells prepared from the lymph nodes from both animals, 5 × 10 8 cells in total, were resuspended with 10 ml anti-coagulated whole blood collected simultaneously from these monkeys. The resuspension was intravenously transferred to another rhesus macaque, MM554. The virological and immunological parameters of the 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 14
Discussion
In this study, we successfully generated a new SHIV strain carrying Env derived from an HIV-1 subtype C primary isolate, HIV-1 97ZA012, utilizing IHR. The presumable advantages of the method employed in the current study over conventional methods utilizing existing/newly generated restriction sites are random utilization of breakpoints within homologous sequences and selection of replication-competent recombinants through multi-round replication in the susceptible cells. These factors may have contributed to the generation of the new SHIV in the current study. In contrast, the IHR-mediated method described in the current study generated replication-competent SHIV 97ZA012 without the requirement for an infectious molecular clone of the parental HIV-1, exploration of appropriate restriction sites, or examination of each plasmid clone for infectivity. This was performed in a considerably shorter time frame in our experience, saving several months compared with conventional methods. However, one would argue that IHR-mediated generation of SHIV does not allow for a detailed genetic analyses, such as mutagenesis of particular gene(s), because of the virus being "swarm." While this is undeniable, the vast majority of currently 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65   16 2000; Worgall et al., 1999) . Therefore, SHIV 97ZA012 may be able to gain entry to cells expressing minimal numbers of receptors/coreceptors, as is SIV 316 (Puffer et al., 2002) .
Whether "CD4-independence" is a property shared by many subtype-C Env or is specific to 97ZA012 or whether a "mosaic" Env protein between HIV-1 89.6 and 97ZA012 caused this notable property remains to be investigated.
This study also presents potential shortcomings of IHR to be resolved in the future. The first drawback is that only a limited variety of Env may function in the C8166-CCR5 cells utilized in the current study, resulting in generation of SHIVs reflecting this potential restriction. Prior to the current study, we inoculated nine primary We were able to detect syncytia formation in the culture transfected with DNA fragments only after 2 weeks. Once syncytia emerged, however, the virus replicated productively in C8166-CCR5 cells and subsequently in RhPBMCs enriched with CD4 + cells and unmanipulated RhPBMCs through a passage in RhPBMCs. SHIV 97ZA012 evolved to be replication competent in RhPBMCs and infectious to RhAMs. The virus may have been replication competent in monkey cells from the beginning. Although HIV-1 97ZA012, which contributed env to SHIV 97ZA012, may have been predisposed to be adequate as a parental virus for generation of SHIV, we have the impression that the method we employed in this study generated a pool of recombinants and selected suitable  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 17 one(s) through in vitro passage. As mentioned above, the recombinant virus that initially emerged was a mixture, and the final genotype(s) was selected and/or evolved through in vitro passage. The only traits of HIV-1 97ZA012 of which we were aware were its replication competence in human PBMCs and its preference for CCR5 as an entry co-receptor to the cells (data not shown).
SHIV 97ZA012 reproducibly replicated to high titers in vivo with a major reduction in pulmonary CD4 + T cells during the acute phase of infection. Considering the paucity of available SHIV strains carrying subtype C Env and a CCR5 co-receptor preference in the field, the virus generated in the current study would immediately fit the interest for evaluation of anti-subtype C vaccine candidates. The virus would be especially useful when the efficacy of antiviral interventions is judged by reduction of the initial peak viral load or prevention of virus-induced depletion of CD4 + T lymphocytes in the effector sites.
Although we successfully generated an SHIV strain competent in tissue culture, the generation of a proficient virus in vivo remains arduous. Indeed, SHIV 97ZA012 replicated to substantially high titers during the acute phase of infection. However, the plasma viral load waned with time, as did SHIV strains generated previously.
Animal-to-animal passage would augment its replication in vivo, as we attempted in this study.
This study has demonstrated the versatility of IHR-mediated generation of SHIV. The method enables utilization of a PCR fragment amplified from uncloned virus as a source for SHIV. This method can be further extended to generate SHIV strains with sequences amplified from clinical samples, such as patient plasma, to strengthen the panel of challenging viruses for evaluation of an anti-HIV vaccine.
Conclusions
By employing IHR, a replication-competent SHIV carrying Env derived from a CCR5-tropic, subtype C HIV-1 97ZA012 strain was generated.
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of cDNA with Super Script III (Life Technologies Corporation) following the manufacturer's instructions. For the reaction, the following primer was utilized:
OFM19-R (5-aggcaagctttattgaggctta-3 at 9604-9625 in HIV-1 HXB2).
Generation of recombinant virus through IHR
Two segments of the SHIV genome (Fragments I and II; Figure 1 HIVvpr-F forward primer (5-agatggaacaagccccagaaga-3 at 5557-5578 in HIV-1 HXB2) and OFM19-R rear primer.
All PCR reactions were conducted with the Expand Long Range dNTPack (Roche Diagnostic Corporation, Basel, Switzerland) under the following conditions: initial denaturation at 94°C for 2 minutes, followed by 10 cycles of amplification consisting of denaturation at 94°C for 15 seconds, annealing at 55°C for 30 seconds, and extension at 68°C for 8 minutes. The reaction was continued with 25 cycles of amplification consisting of denaturation at 94°C for 15 seconds, annealing at 55°C for 30 seconds, and extension at 68°C for 8 minutes (plus 20 seconds at every cycle), followed by a final extension at 68°C for 7 minutes.
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Reyes

Figure Legends

The generated SHIV 97ZA012 carried nearly the entire Env of subtype C isolate 97ZA012.
 SHIV 97ZA012 replicated to high titers in monkey PBMCs, as did SIV239.
 SHIV 97ZA012 was infectious to monkey alveolar macrophages.
The virus caused high viremia and pulmonary CD4 + T-cell depletion during the acute phase.
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